Published: 5 September 2024
Publications
Recent approvals: new active ingredients or new indications
Published: 5 September 2024
Prescriber Update 45(3): 58–59
September 2024
New active ingredients
Table 1 shows recent approval of medicines with new active ingredients gazetted during the period 19 April 2024 to 18 July 2024.
Table 1: Recent approvals of medicines with new active ingredients
| Medicine | New active ingredient | Dose form: strength(s) | Therapeutic area |
|---|---|---|---|
| Aquipta | Atogepant | Tablet: 10mg, 60mg | Migraine |
| Halaven | Eribulin | Solution for injection: 1mg/2mL | Breast cancer (locally advanced or metastatic) Liposarcoma (unresectable) |
| Sarclisa | Isatuximab | Concentrate for injection: 100mg/5mL, 500mg/25mL | Multiple myeloma |
| Tezspire | Tezepelumab | Solution for injection in pre-filled syringe or pen: 210mg | Asthma (severe) |
New indications
There were no approved medicines with new indications for additional therapeutic areas gazetted during the period 19 April 2024 to 18 July 2024.
More information
See the Medsafe website for:
